New drug cocktail aims to tackle tough lung cancer

NCT ID NCT07645222

Recruiting now Disease control Sponsor: Hansoh BioMedical R&D Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This study tests a new drug called HS-20122 in combination with other cancer medicines for people with advanced non-small cell lung cancer. The trial includes three different drug combinations depending on the patient's tumor type. The main goals are to check safety, find the best dose, and see how well the combinations shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HS-20122 combined with aumolertinib, adbrelimab, or platinum-based chemotherapy
What this could lead to: If successful, this could point toward a new combination treatment option for people with advanced non-small cell lung cancer who have run out of standard therapies.
What could go wrong: This is an early phase 1 study, so the main goals are safety and finding the right dose. It is too soon to know if the combinations will work better than existing treatments, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER

Contacts and locations

Locations

Ethics Committee of Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.